NCT02285829

Brief Summary

During lumbar spine fusion surgery intraoperative neurophysiological monitoring is in routine use for prevention of possible nerve injuries during placement of screw into pedicle. Pedicle screw stimulation test is performed to assess if screw placement is encroaching on the nerve roots. Relative distance between the pedicle screw and the neighbouring root can be estimated by the intensity of the current required to activate the root and appropriate muscle. A properly placed screw can be distinguished from those perforating the pedicle wall by its higher minimum level of electrical current needed to elicit a muscle response. The minimum level is deemed as threshold. This test is based on compound muscle action potential (CMAP) and use of neuromuscular blocking agents (NMBA) should be avoided because of possible cause of false negative results of screw stimulation test. Neuromuscular blocking agents, which are in routine use during anesthesia, will have effect on muscle action potential. When NMBA are used current stimulus will depolarize the same number of axons and the associated muscle response will be present but of lower amplitude because some percentage of motor fibers will be blocked by activity of NMBA. At this point, stronger stimulus is needed to recruit additional axons/muscle fibers , and hence, the measured threshold is elevated. Train of four (TOF) test is method used to determine level of neuromuscular blockade, by stimulation of peripheral nerve and following induced muscle contractions. Interpretation of muscle contractions may be by subjective (visual) or objective (quantitative) method. Quantitative TOF test may be used prior screw stimulation test by calculating T4/T1 ratio and obtaining quantitative value which shows level of neuromuscular blockade. Residual neuromuscular blockade may be present before screw stimulation test, and effect on accuracy of this test in this situation was not clearly investigated in recent studies. The purpose of this study would be to determine changes of screw stimulation thresholds under different range of neuromuscular blockade.Therefore, acceptable neuromuscular blockade threshold (determined by TOF test) acceptable for obtaining reliable screw stimulation test should be determined. Screw stimulation test may be performed when neuromuscular blockade is absent and compared to repeated screw stimulation test when neuromuscular blockade is present. Different levels of neuromuscular blockade may provide different results on screw stimulation test, so if difference is statistically significant, induced neuromuscular blockade level may be set as threshold value, acceptable for obtaining reliable testing results.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2014

Completed
11 days until next milestone

First Posted

Study publicly available on registry

November 7, 2014

Completed
3 months until next milestone

Study Start

First participant enrolled

February 11, 2015

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 8, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 8, 2018

Completed
Last Updated

January 18, 2018

Status Verified

January 1, 2018

Enrollment Period

2.9 years

First QC Date

October 27, 2014

Last Update Submit

January 16, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Train of four (TOF) test

    T4/T1 ratio will be determined and measured prior pedicle screw stimulation test, during lumbar spine surgery. Data will be obtained and followed from participants during one day, while surgery is performed.

    TOF test measure will be performed during the day of surgery prior pedicle screw stimulation test

Study Arms (4)

T4/T1=0.1-0.25

Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium, 0.5 µg/kg/min for Cisatracurium ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.1-0.25, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.

Drug: Rocuronium Bromide, Cisatracurium Besylate

T4/T1=0.25-0.50

Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.25-0.50, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.

Drug: Rocuronium Bromide, Cisatracurium Besylate

T4/T1=0.50-0.75

Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.50-0.75, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.

Drug: Rocuronium Bromide, Cisatracurium Besylate

T4/T1=0.75-0.90

Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.75-0.90, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.

Drug: Rocuronium Bromide, Cisatracurium Besylate

Interventions

Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF \>0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.

Also known as: Zemurone, Nimbex
T4/T1=0.1-0.25T4/T1=0.25-0.50T4/T1=0.50-0.75T4/T1=0.75-0.90

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects undergoing elective lumbar spine fusion surgery

You may qualify if:

  • Subjects undergoing lumbar spine fusion surgery with neurophysiologic intraoperative monitoring when pedicle screw stimulation test is performed.
  • Subjects of both gender
  • Age 18-85
  • With diagnosis of lumbar spinal stenosis.
  • All subjects capable of giving informed consent in order to be included for the study.

You may not qualify if:

  • Subjects with medical history of presence of neuromuscular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Langone Medical Center, Hospital for Joint Diseases

New York, New York, 10003, United States

Location

MeSH Terms

Interventions

Rocuroniumcisatracurium

Intervention Hierarchy (Ancestors)

AndrostanolsAndrostanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

  • Aleksandar Beric, MD

    Neurologist

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 27, 2014

First Posted

November 7, 2014

Study Start

February 11, 2015

Primary Completion

January 8, 2018

Study Completion

January 8, 2018

Last Updated

January 18, 2018

Record last verified: 2018-01

Locations